CN121758618A - Pd1和vegfr2双结合剂 - Google Patents
Pd1和vegfr2双结合剂Info
- Publication number
- CN121758618A CN121758618A CN202511932691.3A CN202511932691A CN121758618A CN 121758618 A CN121758618 A CN 121758618A CN 202511932691 A CN202511932691 A CN 202511932691A CN 121758618 A CN121758618 A CN 121758618A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- region amino
- acid sequence
- sequence comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1914747.9 | 2019-10-11 | ||
| GB201914747A GB201914747D0 (en) | 2019-10-11 | 2019-10-11 | PD1 and vegfr2 dual-binding agents |
| GBGB2013180.1A GB202013180D0 (en) | 2019-10-11 | 2020-08-24 | Pd1 and vegfr2 dual-binding agents |
| GB2013180.1 | 2020-08-24 | ||
| PCT/EP2020/078427 WO2021069670A1 (en) | 2019-10-11 | 2020-10-09 | Pd1 and vegfr2 dual-binding agents |
| CN202080075802.2A CN114981301B (zh) | 2019-10-11 | 2020-10-09 | Pd1和vegfr2双结合剂 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080075802.2A Division CN114981301B (zh) | 2019-10-11 | 2020-10-09 | Pd1和vegfr2双结合剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN121758618A true CN121758618A (zh) | 2026-03-31 |
Family
ID=68619556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511932691.3A Pending CN121758618A (zh) | 2019-10-11 | 2020-10-09 | Pd1和vegfr2双结合剂 |
| CN202080075802.2A Active CN114981301B (zh) | 2019-10-11 | 2020-10-09 | Pd1和vegfr2双结合剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080075802.2A Active CN114981301B (zh) | 2019-10-11 | 2020-10-09 | Pd1和vegfr2双结合剂 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20240101674A1 (enExample) |
| EP (3) | EP4041763B1 (enExample) |
| JP (2) | JP7689116B2 (enExample) |
| KR (1) | KR20220091490A (enExample) |
| CN (2) | CN121758618A (enExample) |
| AU (1) | AU2020365021B2 (enExample) |
| CA (2) | CA3156096C (enExample) |
| DK (1) | DK4041763T3 (enExample) |
| ES (1) | ES3027238T3 (enExample) |
| FI (1) | FI4041763T3 (enExample) |
| GB (2) | GB201914747D0 (enExample) |
| HR (1) | HRP20250523T1 (enExample) |
| HU (1) | HUE071341T2 (enExample) |
| IL (1) | IL292158A (enExample) |
| LT (1) | LT4041763T (enExample) |
| PL (1) | PL4041763T3 (enExample) |
| PT (1) | PT4041763T (enExample) |
| RS (1) | RS66837B1 (enExample) |
| SI (1) | SI4041763T1 (enExample) |
| WO (1) | WO2021069670A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
| CN116143935A (zh) * | 2021-11-22 | 2023-05-23 | 杭州翰思生物医药有限公司 | 重组抗体及其应用 |
| CN119654343A (zh) * | 2022-08-09 | 2025-03-18 | 上海济煜医药科技有限公司 | 一种靶向pd-1和vegf的抗体及其应用 |
| CN118620082A (zh) * | 2023-03-10 | 2024-09-10 | 南京维立志博生物科技有限公司 | 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途 |
| WO2026150132A1 (en) | 2025-01-12 | 2026-07-16 | BioNTech SE | Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| ES2742379T3 (es) * | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| MA43028B1 (fr) | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| CN109893654B (zh) * | 2017-12-11 | 2021-07-27 | 江苏恒瑞医药股份有限公司 | Vegfr抑制剂治疗肿瘤的方法 |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| JP7883848B2 (ja) | 2018-11-06 | 2026-07-02 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 腫瘍を治療するための薬物の調製におけるファミチニブと組み合わせた抗ｐｄ－１抗体の使用 |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
-
2019
- 2019-10-11 GB GB201914747A patent/GB201914747D0/en not_active Ceased
-
2020
- 2020-08-24 GB GBGB2013180.1A patent/GB202013180D0/en not_active Ceased
- 2020-10-09 EP EP20789105.2A patent/EP4041763B1/en active Active
- 2020-10-09 SI SI202030611T patent/SI4041763T1/sl unknown
- 2020-10-09 JP JP2022521074A patent/JP7689116B2/ja active Active
- 2020-10-09 CA CA3156096A patent/CA3156096C/en active Active
- 2020-10-09 CA CA3289307A patent/CA3289307A1/en active Pending
- 2020-10-09 PL PL20789105.2T patent/PL4041763T3/pl unknown
- 2020-10-09 AU AU2020365021A patent/AU2020365021B2/en active Active
- 2020-10-09 EP EP25212556.2A patent/EP4671279A3/en active Pending
- 2020-10-09 FI FIEP20789105.2T patent/FI4041763T3/fi active
- 2020-10-09 KR KR1020227014433A patent/KR20220091490A/ko active Pending
- 2020-10-09 LT LTEPPCT/EP2020/078427T patent/LT4041763T/lt unknown
- 2020-10-09 US US17/768,013 patent/US20240101674A1/en not_active Abandoned
- 2020-10-09 ES ES20789105T patent/ES3027238T3/es active Active
- 2020-10-09 CN CN202511932691.3A patent/CN121758618A/zh active Pending
- 2020-10-09 HU HUE20789105A patent/HUE071341T2/hu unknown
- 2020-10-09 EP EP25159487.5A patent/EP4570824A3/en not_active Withdrawn
- 2020-10-09 HR HRP20250523TT patent/HRP20250523T1/hr unknown
- 2020-10-09 DK DK20789105.2T patent/DK4041763T3/da active
- 2020-10-09 CN CN202080075802.2A patent/CN114981301B/zh active Active
- 2020-10-09 PT PT207891052T patent/PT4041763T/pt unknown
- 2020-10-09 WO PCT/EP2020/078427 patent/WO2021069670A1/en not_active Ceased
- 2020-10-09 RS RS20250448A patent/RS66837B1/sr unknown
-
2022
- 2022-04-11 IL IL292158A patent/IL292158A/en unknown
-
2025
- 2025-02-18 US US19/056,312 patent/US12479920B2/en active Active
- 2025-05-26 JP JP2025087525A patent/JP2025134713A/ja active Pending
- 2025-10-22 US US19/366,430 patent/US20260167726A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109963591B (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| EP3808376A1 (en) | Antibody targeting cldn18.2, bispecific antibody, adc, and car, and applications thereof | |
| CN114981301B (zh) | Pd1和vegfr2双结合剂 | |
| CN116261595A (zh) | 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| US20230295311A1 (en) | Anti c-met antibodies | |
| JP2024513921A (ja) | 抗ｃｄ１２２抗体及びその使用 | |
| JP7843824B2 (ja) | 抗体および使用方法 | |
| JP7578289B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| CN111819199A (zh) | Pd1结合剂 | |
| CN117279950B (zh) | 一种靶向il-18bp的抗体及其应用 | |
| CN111295395B (zh) | 抗体和使用方法 | |
| CN111788229A (zh) | Csf1r结合剂 | |
| RU2761638C1 (ru) | Антитела против лиганда программируемой смерти (pd-l1) и их применение | |
| HK40075900A (en) | Pd1 and vegfr2 dual-binding agents | |
| HK40075900B (en) | Pd1 and vegfr2 dual-binding agents | |
| HK40129808A (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
| JP2025532758A (ja) | 癌の治療における使用のためのｂｔｎ３ａ活性化抗体、ｂｃｌ２阻害剤及び低メチル化剤の併用 | |
| CN120882746A (zh) | 结合至nkg2a和pd-l1的药剂及其用途 | |
| HK40046942A (en) | Antibody targeting cldn18.2, bispecific antibody, adc, and car, and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |